Following on from the previous podcast episode involving a discussion on the US biosimilar landscape, CBPartners’ experts explored trends and dynamics of the biosimilar market ex-USA – across the EU, Latin America and Asia, with a focus on:  Biosimilar availability and uptake in each region Key...

As the costs of biologic drugs increase, biosimilars have emerged as an appealing option for controlling costs and expanding access to treatment. While the uptake of biosimilars in the USA started off slowly, it has since gained a rapid pace.  In the first of a multi-part biosimilar series,...